James Brumley

James Brumley

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He’s now primarily a freelance writer, tapping more than a decade’s worth of broad experience to help investors get more out of the market.

With a background in technical analysis as well as fundamental analysis, James writes with a multifaceted philosophy that combines the importance of company performance with the power of stock-trade timing. His commentary is as apt to focus on a chart as it is earnings, as he believes this dual approach is the only way an investor has a shot at consistently beating the market.

James’ work has appeared at several websites, including Street Authority, Motley Fool, Kapitall and Investopedia. When not writing as a journalist, James works on his book explaining his multipronged approach to investing.

Recent Articles

Why Alibaba Group Holding Ltd (BABA) Stock Is a Survivor

BABA stock holders may fear the war against bootlegged goods could crimp Alibaba's revenue, but there's an unspoken "wink wink" reality that has to be understood.

Why Davita Inc (DVA), J C Penney Company Inc (JCP) and Acuity Brands, Inc. (AYI) Are 3 of Today’s Worst Stocks

Davita (DVA), JCPenney (JCP) and Acuity Brands (AYI) investors were wishing the weekend lasted one more day on Monday.

10 Companies That Should Fear Donald Trump’s “America First” Plans

The "America First" initiative put into place by President-elect Donald Trump won't be entirely devoid of adverse consequences. These companies have the most to lose.

Apple Inc. (AAPL) iPhone 10th Birthday Also Marks the End of an Era

The iPhone, from Apple (AAPL), first debuted a decade ago to rave reviews. The magic from then is almost undetectable now.

Why Regeneron Pharmaceuticals Inc (REGN), Teva Pharmaceutical Industries Ltd ADR (TEVA) and AT&T Inc. (T) Are 3 of Today’s Worst Stocks

Teva Pharmaceutical (TEVA), AT&T (T) and Regeneron Pharmaceuticals (REGN) never even had a prayer of making gains on Friday.